A qualitative study on pharmacist prescribing for patients with chronic kidney disease.

Alraiisi, Fatma; Stewart, Derek; Alnaamani, Hamed; Fahmy, Mustafa; Cunningham, Scott

Abstract

Background and Objective: Chronic Kidney Disease has a high risk of morbidity and mortality. The available evidence worldwide demonstrates that nonmedical prescribing by pharmacist in various clinical specialties is safe and effective approach. There is lack of evidence of information on the implementation and development of pharmacist prescribing for patients with chronic kidney disease (CKD). The aim of this research was to explore the development, implementation and evaluation of pharmacist prescribing for patients with Chronic Kidney Disease (CKD) in the UK. Setting and Method: This study used a qualitative semi-structured interview. The development of the theory based semi-structured interview tool followed a rigorous iterative process using findings from literature, underpinned with CFIR and reviewed independently by an expert panel. A date/time for a telephone interview was arranged following receipt of signed consent. All interviews were transcribed verbatim. Interview data were analysed thematically. The Francis method of checking for data saturation was used. Ethical approval was granted by RGU School of Pharmacy. Main outcome measures: Themes generated as mapped by the CFIR relevant constructs. Facilitators and barriers to implementation of the prescribing services for patients with CKD. Results: Data saturation was reached after 14 interviews. Demographic details included: 11 female, 7 had >16 year experience in profession, all had secondary care as main practice setting and 8 had >11 years as a prescriber. The interviewees were generally very positive about their prescribing practice and they articulated that they were prescribing in a variety of settings. CFIR helped identify themes related to facilitators and barriers to advancing prescribing practice. There was enthusiasm for the future development of prescribing practice including further establishment of clinics and taking responsibility for groups of patients. Conclusion: This work provides information relating to the current status of the development of pharmacist prescribing practice in the UK. Further 'deep dive' case study work will help explore the practice of leading edge advanced and consultant level practitioners to learn even more about practice development.

Citation

ALRIISI, F.A., STEWART, D., ALNAAMANI, H., FAHMY, M. and CUNNINGHAM, S. 2022. A qualitative study on pharmacist prescribing for patients with chronic kidney disease. Presented at 2022 ESCP (European Society of Clinical Pharmacy) Spring workshop: taking care of patients with neurological disorders, 28-29 April 2022, Zürich, Switzerland.

• Presentation Conference Type: Poster
• Conference Name: 2022 ESCP (European Society of Clinical Pharmacy) Spring workshop: taking care of patients with neurological disorders
• Start Date: Apr 28, 2022
• End Date: Apr 29, 2022
• Deposit Date: Jul 21, 2022
• Publicly Available Date: Jul 21, 2022
• Peer Reviewed: Peer Reviewed
• DOI: https://doi.org/10.1007/s11096-022-01432-5
• Keywords: Chronic kidney disease (CKD); Morbidity; Mortality; Non-medical prescribing; Pharmacist
• Public URL: https://rgu-repository.worktribe.com/output/1705780
• Additional Information: Abstract published as:; ALRIISI, F.A., STEWART, D. and CUNNINGHAM, S. 2022. Theoratically based qualitative study on pharmacist prescribing for patients with chronic kidney disease. International journal of clinical pharmacy [online], 44(3): 2022 ESCP (European Society of Clinical Pharmacy) Spring workshop: taking care of patients with neurological disorders, 28-29 April 2022, 19-21 October 2021, Zürich, Switzerland, article PP03. Available from: https://link.springer.com/article/10.1007/s11096-022-01432-5#Sec17